Early-stage funding for European life sciences companies

We are a venture capital firm specialised in seed investment for innovative early stage European companies.

Our current portfolio comprises biotech, medtech and diagnostics companies, all working to develop truly disruptive solutions for high unmet medical needs.

Dezima and Acerta, multi-billion Euro success stories

BioGeneration was co-founder and investor in two of the most successful biotech startups in Europe: Acerta Pharma and Dezima Pharma. Acerta Pharma develops a new drug for the treatment of hematologic malignancies (leukemia) and was sold to AstraZeneca for up to US$ 7 billion. Dezima Pharma is developing a treatment for of a cardiovascular disorder (dyslipidemia) and was sold to Amgen for a deal amount of up to US$ 1.5 billion.

Shaping new life-science ventures

Our varied and complementary experience has been gained from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest news

Scenic Biotech: one of Nature Biotechnology Academic Spinouts of 2017

We congratulate Scenic Biotech on being one of Nature Biotechnology Academic Spinouts of 2017. Nature Biotechnology: "... we believe these companies represent some of the best (and most richly financed) science that was commercialized from academia in 2017". Please...

Next events

BioFit, 4-5 December 2018

Daniela Couto will be attending the BioFit conference on 4-5 December 2018 in Lille. You can connect with Daniela via email to set up a meeting. https://www.biofit-event.com/

Latest investments

Subscribe to BGV news updates

Join our mailing list to receive the latest news and updates from our team.

Please check your email to complete your subscription.